Freeline reports Q1 results

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.

Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy

To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.

		Three Months Ended March 31,
		2021		2020
	OPERATING EXPENSES:
	Research and development	$ 23,863		$ 17,457
	General and administrative	10,078		3,735
	Total operating expenses	33,941		21,192
	LOSS FROM OPERATIONS:	(33,941)		(21,192)
	OTHER INCOME (EXPENSE) NET:
	Other income (expense), net	(1,733)		863
	Interest income, net	140		53
	Benefit from R&D tax credit	598		3,702
	Total other income (expense), net	(995)		4,618
	Loss before income taxes	(34,936)		(16,574)
	Income tax expense	(9)		(131)
	Net loss	(34,945)		(16,705)
	Net loss per share attributable to ordinary shareholders-basic and diluted	$ (0.98)		$ (1.85)
	Weighted average ordinary shares outstanding-basic and diluted	35,655,443		9,010,843
			March 31,		December 31,
			2021		2020
ASSETS
CURRENT ASSETS:
Cash and cash equivalents			$ 195,765		$ 229,974
Account receivable			-		97
Prepaid expenses and other current assets			27,718		28,105
Total current assets			223,483		258,176
Property and equipment, net			10,093		8,608
Intangible assets, net			16		23
Other non-current assets			1,655		1,805
Total assets			$ 235,247		$ 268,612
LIABILITIES, PREFERRED SHARES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable			$ 5,528		$ 8,093
Accrued expenses and other current liabilities			10,292		10,719
Total current liabilities			15,820		18,812
Total liabilities			15,820		18,812
Commitments and contingencies
SHAREHOLDERS' EQUITY:
Deferred shares			137		155
Additional paid-in capital			458,857		456,293
Accumulated other comprehensive loss			11,368		9,342
Accumulated deficit			(250,935)		(215,990)
Total shareholders' equity			219,427		249,800
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY			$ 235,247		$ 268,612

Companies

UK 100

Latest directors dealings